These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 33546983)

  • 1. Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression.
    Mosterd CM; Kanbay M; van den Born BJH; van Raalte DH; Rampanelli E
    Best Pract Res Clin Endocrinol Metab; 2021 May; 35(3):101484. PubMed ID: 33546983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of CKD on Uremic Toxins and Gut Microbiota.
    Rysz J; Franczyk B; Ławiński J; Olszewski R; Ciałkowska-Rysz A; Gluba-Brzózka A
    Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33807343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal Microbiota in Type 2 Diabetes and Chronic Kidney Disease.
    Sabatino A; Regolisti G; Cosola C; Gesualdo L; Fiaccadori E
    Curr Diab Rep; 2017 Mar; 17(3):16. PubMed ID: 28271466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus.
    Kanbay M; Onal EM; Afsar B; Dagel T; Yerlikaya A; Covic A; Vaziri ND
    Int Urol Nephrol; 2018 Aug; 50(8):1453-1466. PubMed ID: 29728993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis.
    Rukavina Mikusic NL; Kouyoumdzian NM; Choi MR
    Pflugers Arch; 2020 Mar; 472(3):303-320. PubMed ID: 32064574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal microbiome diversity of diabetic and non-diabetic kidney disease: Current status and future perspective.
    Das S; Gnanasambandan R
    Life Sci; 2023 Mar; 316():121414. PubMed ID: 36682521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role and mechanism of gut microbiota-derived short-chain fatty in the prevention and treatment of diabetic kidney disease.
    Tao P; Ji J; Wang Q; Cui M; Cao M; Xu Y
    Front Immunol; 2022; 13():1080456. PubMed ID: 36601125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical impact of gut microbiota in chronic kidney disease.
    Kim SM; Song IH
    Korean J Intern Med; 2020 Nov; 35(6):1305-1316. PubMed ID: 32872729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathomechanism and treatment of gut microbiota dysbiosis in chronic kidney disease and interventional effects of Chinese herbal medicine].
    Han WB; Liu YL; Wan YG; Sun W; Tu Y; Yang JJ; Wu W; He WM; Yao J
    Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(13):2425-2432. PubMed ID: 28840678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota.
    Ni Y; Zheng L; Nan S; Ke L; Fu Z; Jin J
    Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(10):1406-1420. PubMed ID: 36239349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiota and its metabolites - molecular mechanisms and management strategies in diabetic kidney disease.
    Mao ZH; Gao ZX; Liu DW; Liu ZS; Wu P
    Front Immunol; 2023; 14():1124704. PubMed ID: 36742307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tangshen Formula alleviates inflammatory injury against aged diabetic kidney disease through modulating gut microbiota composition and related amino acid metabolism.
    Chen DQ; Zhang HJ; Zhang W; Feng K; Liu H; Zhao HL; Li P
    Exp Gerontol; 2024 Apr; 188():112393. PubMed ID: 38458480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential mechanism of gut microbiota-microbial metabolites-mitochondrial axis in progression of diabetic kidney disease.
    Ma L; Zhang L; Li J; Zhang X; Xie Y; Li X; Yang B; Yang H
    Mol Med; 2023 Oct; 29(1):148. PubMed ID: 37907885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease.
    Zaky A; Glastras SJ; Wong MYW; Pollock CA; Saad S
    Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal dysbiosis activates renal renin-angiotensin system contributing to incipient diabetic nephropathy.
    Lu CC; Ma KL; Ruan XZ; Liu BC
    Int J Med Sci; 2018; 15(8):816-822. PubMed ID: 30008592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of gut microbiota on kidney function and pathogenesis.
    Mahmoodpoor F; Rahbar Saadat Y; Barzegari A; Ardalan M; Zununi Vahed S
    Biomed Pharmacother; 2017 Sep; 93():412-419. PubMed ID: 28654798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiota and prebiotics modulation of uremic toxin generation.
    Koppe L; Fouque D
    Panminerva Med; 2017 Jun; 59(2):173-187. PubMed ID: 28001024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Traditional Chinese medicine improved diabetic kidney disease through targeting gut microbiota.
    Wu XQ; Zhao L; Zhao YL; He XY; Zou L; Zhao YY; Li X
    Pharm Biol; 2024 Dec; 62(1):423-435. PubMed ID: 38757785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of gut microbiota: How it could play roles beyond the digestive system on development of cardiovascular and renal diseases.
    Suganya K; Son T; Kim KW; Koo BS
    Microb Pathog; 2021 Mar; 152():104583. PubMed ID: 33164814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiome in chronic kidney disease: challenges and opportunities.
    Nallu A; Sharma S; Ramezani A; Muralidharan J; Raj D
    Transl Res; 2017 Jan; 179():24-37. PubMed ID: 27187743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.